BMRN
Biomarin Pharmaceutical Inc
63.40$
-1.1%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +18.8% | +25.5% | +17.6% | +13.5% | +14.3% | +9.2% | -0.8% | +13.5% | +15.4% | +18.0% | +12.9% | |
| – | +24.3% | +37.9% | +15.3% | +30.4% | +14.0% | +45.8% | -10.3% | +6.9% | +5.8% | +9.1% | +27.0% | |
| – | +17.7% | +23.0% | +18.1% | +9.7% | +14.3% | -0.6% | +3.0% | +15.8% | +18.5% | +20.5% | +9.3% | |
| – | +37.5% | +4.3% | -7.7% | +14.0% | +2.7% | -12.2% | +0.1% | +3.3% | +15.0% | +0.1% | +23.4% | |
| – | +33.1% | +18.5% | +16.3% | -49.5% | +6.6% | +11.9% | +6.0% | +5.2% | +8.3% | +31.8% | +116.6% | |
| – | +17.9% | +101.6% | -36.5% | +19.6% | +11.2% | -4.5% | +5.7% | -1.8% | +18.8% | +5.2% | +9.0% | |
| – | – | – | – | – | – | – | – | – | +15.4% | +160.6% | +10.2% | |
| – | +4.4% | +3.3% | +8.1% | +2.2% | -46.3% | +24.9% | -47.7% | +4.1% | +8.5% | -26.9% | -14.0% | |
| – | – | – | – | – | – | – | – | – | +26.1% | +187.3% | -10.9% | |
| – | +87.6% | -1,276.2% | – | -180.7% | – | – | – | – | +161.0% | +449.3% | +16.3% | |
| – | – | – | – | – | – | – | -107.5% | – | +18.4% | +154.6% | -18.3% | |
| – | – | – | – | -103.7% | – | +162.1% | -43.3% | +459.4% | +15.6% | +112.1% | -11.9% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.